Pangen Biotech Inc.
222110
企业摘要
季度业绩走势
营业收入
营业利润率
市场偏好度
※ 点击图表可查看该月份的AI分析信息。
营业收入
合并
单独
营业利润
合并
单独
净利润
合并
单独
财务信息
保存为Excel
该期间没有财务信息数据。
~
季度
决算
*单位基准小数点第四位以下的数值标记为'0/-0'
财务指标预测
※ 本预测值是基于历史数据的AI简单估算值，可能与实际业绩存在差异。
企业概况
截至2026年6月
Pangen Biotech Inc. built GMP facilities for biopharmaceutical production from its early days, and using these GMP facilities together with its proprietary PanGen CHO-TECH(TM) technology and biopharmaceutical commercialization technology, the company carries out the following businesses: the production and sale of the biosimilar EPO drug; contract manufacturing (CMO) and development technology transfer services (CDO) for biopharmaceuticals, including non-clinical and clinical samples; and biopharmaceutical development. Biosimilar drug production and sale business: EPO drug, an anemia treatment for chronic renal failure patients. Biopharmaceutical CMO and development technology transfer (CDO) business: CDMO (Contract Development and Manufacturing Organization). Biopharmaceutical development business: Factor VIII, a treatment for hemophilia A; Aflibercept, a treatment for macular degeneration and macular edema; an anti-SFTSV antibody treatment for severe fever with thrombocytopenia syndrome; and G-CSF, an adjuvant for cancer treatment. The biosimilar EPO drug, an anemia treatment for chronic renal failure patients that the company successfully developed on its own, received marketing authorization under the product name Erysaa from the Malaysian health authority in January 2019 and has been sold in the Malaysian market since March 2019; it received marketing authorization under the product name Panpotin in Korea in November 2019 and domestic sales began in February 2020; in the Philippines it received marketing authorization for 4000 IU (product name Erysaa) in August 2022 and for 2000 IU (product name Erysaa) in October 2022, and has been sold there since December 2022; and in Saudi Arabia it obtained marketing authorization (product name: Panpotin) in May 2023 and has been sold there since March 2024.
代表理事
Yoon Jaeseung
成立日期
2010年1月29日
法人类型
韩国创业板
行业分类
Manufacture of medicaments
法人注册号
13111-0248194
营业执照号
129-86-42227
电话号码
031-733-9165
传真号码
031-733-9167
公司地址
306 Sinwon-ro, Yeongtong-gu, Suwon-si, Gyeonggi-do
产品与服务
评论